Increase your knowledge of acute lymphoblastic leukemia with insights from the experts on current and future therapeutic strategies
Jun 22, 2017
Jun 22, 2018
- David I. Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
Diagnosis and risk assessment of acute lymphoblastic leukemia in 2017
- Dieter Hoelzer, MD, PhD, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany
Making the most of induction therapy in acute lymphoblastic leukemia
- Robin Foà, MD, University of Rome, Rome, Italy
Minimal residual disease and risk-adapted post-remission therapy
- Max S. Topp, MD, University of Würzburg, Würzburg, Germany
New strategies for relapsed/refractory acute lymphoblastic leukemia
This educational activity is designed for hematologists, medical oncologists, and other healthcare providers involved in the management of patients with acute lymphoblastic leukemia.
After successful completion of this educational activity, participants should be able to:
- Distinguish standard-risk versus high-risk patients with acute lymphoblastic leukemia based upon disease-specific and patient-specific factors
- Integrate age-adapted protocols into initial therapy of patients with acute lymphoblastic leukemia
- Identify patients with acute lymphoblastic leukemia who may avoid allogeneic stem cell transplant in first remission based upon minimal residual disease status and post-induction risk
This educational activity is supported by a grant from Shire.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.